AstraZeneca is set to acquire biotechnology firm EsoBiotec for up to $1 billion, including a $425 million upfront payment and up to $575 million contingent on milestones. EsoBiotec's ENaBL platform facilitates rapid cell therapy treatments. The transaction is anticipated to close in Q2 2025, with no impact on AstraZeneca's 2025 financial guidance.